Article
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Feb 2014
Watanabe Satoshi, Minegishi Yuji, Yoshizawa Hirohisa, Maemondo Makoto, Inoue Akira, Sugawara Shunichi, Isobe Hiroshi, Harada Masao, Ishii Yoshiki, Gemma Akihiko, Hagiwara Koichi, Kobayashi Kunihiko
Abstract excerpt
INTRODUCTION: In non-small-cell lung cancer, an exon 19 deletion and an L858R point mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to EGFR-tyrosine kinase inhibitors. However, it is uncertain whether other uncommon EGFR mutations are associated with sensitivity to EGFR-tyrosine kinase inhibitors. METHODS: A post-hoc analysis to assess prognostic factors was performed with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.